Inhibition of miR-331-3p and miR-9-5p ameliorates Alzheimer's disease by enhancing autophagy
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Our study suggests that using miR-331-3p and miR-9-5p, along with autophagic activity and amyloid plaques may distinguish early versus late stage of AD for more accurate and timely diagnosis. Additionally, we further provide a possible new therapeutic strategy for AD patients by inhibiting miR-331-3p and miR-9-5p and enhancing autophagy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Morris water maze: procedures for assessing spatial and related forms of learning and memory
Vorhees, C. V., & Williams, M. T. (2006) · Nature Protocols · doi:10.1038/nprot.2006.116 · Cited by 4,629 · cited 1×
“A spatial memory test was performed as previously described with minor modifications [49].”
MethodLoss of autophagy in the central nervous system causes neurodegeneration in mice
Komatsu, M., Waguri, S., Chiba, T., Murata, S., Iwata, J.-I., Tanida, I., Ueno, T., Koike, M., Uchiyama, Y., Kominami, E., et al. (2006) · Nature · doi:10.1038/nature04723 · Cited by 3,500 · cited 1×
“Studies reported previously that activating autophagy could benefit the brain microenvironment supporting the neuronal cell survival [39, 40].”
BackgroundThe neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · cited 1×
“AD is an irreversible, progressive brain disorder characterized by memory loss and cognitive decline [1, 2].”
BackgroundAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“Neutralization of Aβ by aducanumab showed a promising perspective for the clinical treatment of AD [15, 16].”
BackgroundMicroglia-specific localisation of a novel calcium binding protein, Iba1
Ito, D., Imai, Y., Ohsawa, K., Nakajima, K., Fukuuchi, Y., & Kohsaka, S. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00040-0 · Cited by 1,476 · cited 1×
“Immunofluorescent staining of ionized calcium-binding adapter molecule 1 (IBA1, a microglia marker [26]), cluster of differentiation 68 (CD68, highly expressed in activated microglia [27-29]), microtubule-associated protein 2 (MAP2, a neuron marker [30]) showed more activated microglia cells and less neurons in AD mic…”
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease
Ulland, T. K., Song, W. M., Huang, S. C.-C., Ulrich, J. D., Sergushichev, A., Beatty, W. L., Loboda, A. A., Zhou, Y., Cairns, N. J., Kambal, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.023 · Cited by 1,263 · cited 1×
“The dysfunction of autophagy led to Aβ and tau accumulation and promoted progression of AD [20, 21].”
BackgroundSelf-citationHopperton, K. E., Mohammad, D., Trépanier, M. O., Giuliano, V, & Bazinet, R. P. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.246 · Cited by 622 · cited 1×
“Activated microglia is reported to be elevated in AD patients [41, 42].”
BackgroundHeckmann, B. L., Teubner, B. J. W., Tummers, B., Boada-Romero, E., Harris, L., Yang, M., Guy, C. S., Zakharenko, S. S., & Green, D. R. (2019) · Cell · doi:10.1016/j.cell.2019.05.056 · Cited by 503
A resurrection of aducanumab for Alzheimer's disease
Schneider, L. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30480-6 · Cited by 286 · cited 1×
“Neutralization of Aβ by aducanumab showed a promising perspective for the clinical treatment of AD [15, 16].”
Background
Cited by
Emerging role of non-coding RNAs in neuroinflammation mediated by microglia and astrocytes
Yang, R., Yang, B., Liu, W., Tan, C., Chen, H., & Wang, X. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02856-0 · Cited by 91
“AD miR-331-3p Sequestosome 1 Ameliorates Alzheimer’s disease by enhancing autophagy [37]”
BackgroundInfluentialEmergence of Extracellular Vesicles as “Liquid Biopsy” for Neurological Disorders: Boom or Bust
Kumar, A., Nader, M. A., & Deep, G. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000788 · Cited by 79
“…miR-9, a brain-specific miRNA highly expressed in the brain to regulate several cellular and developmental processes (Kapsimali et ; Coolen et al., 2013; Millan, 2017), has shown higher expression levels in late-stage AD in brain tissues compared with controls (Lukiw, 2012; Chen et al., 2021b).”
BackgroundTargeting autophagy in Alzheimer’s disease: Animal models and mechanisms
Zhang, X.-W., 澳门大学中华医药研究院中药质量研究国家重点实验室, 澳. 凼. 9., State Key Laboratory of Quality Research in Chinese Medicine, I. O. C. M. S., Zhu, X.-X., Tang, D.-S., Lu, J.-H., 佛山大学广东省动物分子设计与精准育种重点实验室, 广., & Guangdong Provincial Key Laboratory of Animal Molecular Design and Precise Breeding, G. E. T. C. O. G. P. (2023) · Zoological Research · doi:10.24272/j.issn.2095-8137.2023.294 · Cited by 77
Liu, X., Shen, L., Wan, M., Xie, H., & Wang, Z. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02428-1 · Cited by 33
Self-citation
Metadata
- Authors
- Chen, M.-L., Hong, C.-G., Yue, T., Li, H.-M., Duan, R., Hu, W.-B., Cao, J., Wang, Z.-X., Chen, C.-Y., Hu, X.-K., Wu, B., Liu, H.-M., Tan, Y.-J., Liu, J.-H., Luo, Z.-W., Zhang, Y., Rao, S.-S., Luo, M.-J., Yin, H., Wang, Y.-Y., Xia, K., Tang, S.-Y., Xie, H., & Liu, Z.-Z.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2021
- Volume
- 11
- Issue
- 5
- Pages
- 2395-2409
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W3110924675
- Cited by
- 163
- References
- 16
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.